ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
PLoS ONE
◽
10.1371/journal.pone.0199642
◽
2018
◽
Vol 13
(7)
◽
pp. e0199642
◽
Cited By ~ 10
Author(s):
Maria Giuseppa Vitale
◽
Sarah Scagliarini
◽
Luca Galli
◽
Sandro Pignata
◽
Giovanni Lo Re
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Elderly Patients
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Safety Data
◽
Efficacy And Safety
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Related Documents
Cited By
References
Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
Annals of Oncology
◽
10.1093/annonc/mdx371.051
◽
2017
◽
Vol 28
◽
pp. v318
Author(s):
R. Sabbatini
◽
L. Galli
◽
S. Pignata
◽
G. Lo Re
◽
F. Valcamonico
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Elderly Patients
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Safety Data
◽
Efficacy And Safety
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Annals of Oncology
◽
10.1016/j.annonc.2021.08.092
◽
2021
◽
Vol 32
◽
pp. S709
Author(s):
S.E. Rebuzzi
◽
A. Signori
◽
M. Maruzzo
◽
G. Tortora
◽
L. Galli
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
First Line
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
7148 POSTER Hyperglycemia and Hypercholesterolemia and Associated Outcomes of Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus in the Expanded-access Program REACT
European Journal of Cancer
◽
10.1016/s0959-8049(11)72063-9
◽
2011
◽
Vol 47
◽
pp. S519
◽
Cited By ~ 1
Author(s):
P. Bono
◽
D. Kim
◽
A. Panneerselvam
◽
V. Grünwald
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis
Future Oncology
◽
10.2217/fon.15.241
◽
2015
◽
Vol 11
(21)
◽
pp. 2893-2903
◽
Cited By ~ 2
Author(s):
Sergio Bracarda
◽
Sylvie Rottey
◽
Amit Bahl
◽
Christian Eichelberg
◽
Begoña Mellado
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Real World
◽
Renal Cell
◽
Real World Data
◽
World Data
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
Annals of Oncology
◽
10.1093/annonc/mdx371.041
◽
2017
◽
Vol 28
◽
pp. v314
Author(s):
S. Bracarda
◽
L. Galli
◽
M. Maruzzo
◽
G. Lo Re
◽
S. Buti
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Prognostic Factors
◽
Clinical Outcome
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)
Annals of Oncology
◽
10.1093/annonc/mdy283.102
◽
2018
◽
Vol 29
◽
pp. viii317
Author(s):
A. Gomez de Liano Lista
◽
B. Venugopal
◽
K. Fife
◽
S. Symeonides
◽
N.S. Vasudev
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Future Oncology
◽
10.2217/fon-2017-0570
◽
2018
◽
Vol 14
(14)
◽
pp. 1347-1354
◽
Cited By ~ 2
Author(s):
Sergio Bracarda
◽
Luca Galli
◽
Marco Maruzzo
◽
Giovanni Lo Re
◽
Sebastiano Buti
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Prognostic Factors
◽
Clinical Outcome
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)
Annals of Oncology
◽
10.1093/annonc/mdy283.094
◽
2018
◽
Vol 29
◽
pp. viii314
Author(s):
E. Verzoni
◽
G. Cartenì
◽
E. Cortesi
◽
F. Roila
◽
M.G. Vitale
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Adverse Events
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Activity Data
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Journal for ImmunoTherapy of Cancer
◽
10.1186/s40425-019-0579-z
◽
2019
◽
Vol 7
(1)
◽
Cited By ~ 28
Author(s):
Elena Verzoni
◽
◽
Giacomo Cartenì
◽
Enrico Cortesi
◽
Diana Giannarelli
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Adverse Events
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Real World
◽
Renal Cell
◽
Efficacy And Safety
◽
Expanded Access Program
◽
Previously Treated
◽
Access Program
Download Full-text
SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS
The Journal of Urology
◽
10.1016/s0022-5347(08)61225-2
◽
2008
◽
Vol 179
(4S)
◽
pp. 418-418
Author(s):
Cora N Sternberg
◽
Camillo Porta
◽
Sergio Bracarda
◽
Giacomo Carteni
◽
Giovanni Lo Re
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Preliminary Assessment
◽
Safety And Efficacy
◽
Expanded Access
◽
Expanded Access Program
◽
Access Program
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close